drugset / Trial / NCT05430399
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Phase 3
Recruiting
349 enrolled
Sun Yat-sen University
Beijing Biostar Pharmaceuticals Co., Ltd. · collabHunan Cancer Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.
Timeline
- Start
- 2022-06-21
- Primary completion
- 2025-06-01
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Epothilone D | Small molecule | 40 mg/m2 | — |